Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKT Alkami Technology	$26.08 -0.7%	$30.47	$22.65 ▼ $42.29	$2.71B	0.49	720,827 shs	721,476 shs
APDN Applied DNA Sciences	$1.64 -2.4%	$6.29	$1.45 ▼ $450.00	$1.81M	0.44	872,696 shs	91,439 shs
DY Dycom Industries	$152.18 -1.9%	$169.56	$133.00 ▼ $207.20	$4.41B	1.34	511,917 shs	1,023 shs
GDYN Grid Dynamics	$15.31 -2.2%	$19.74	$9.07 ▼ $25.50	$1.30B	1.1	585,757 shs	577,878 shs
IOVA Iovance Biotherapeutics	$3.22 -1.1%	$4.78	$3.19 ▼ $14.23	$1.05B	1.05	7.13 million shs	87,590 shs
NVAX Novavax	$5.81 -3.2%	$8.04	$3.81 ▼ $23.86	$934.50M	2.92	8.00 million shs	23,150 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKT Alkami Technology	+1.07%	-3.95%	-13.98%	-27.67%	+11.99%
APDN Applied DNA Sciences	+1.20%	-20.00%	-76.29%	-83.53%	-99.60%
DY Dycom Industries	+1.20%	-4.27%	-5.62%	-11.14%	+10.78%
GDYN Grid Dynamics	-0.83%	-6.95%	-17.53%	-30.22%	+29.98%
IOVA Iovance Biotherapeutics	-2.40%	-6.61%	-23.35%	-56.08%	-77.10%
NVAX Novavax	-6.40%	-20.63%	-27.97%	-25.37%	+29.03%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKT Alkami Technology	2.7204 of 5 stars	3.4	2.0	0.0	2.7	3.3	0.6
APDN Applied DNA Sciences	2.0075 of 5 stars	3.5	4.0	0.0	2.3	0.0	0.0
DY Dycom Industries	4.7234 of 5 stars	3.6	5.0	2.6	3.5	2.5	1.9
GDYN Grid Dynamics	2.8401 of 5 stars	3.6	3.0	0.0	3.6	2.5	0.0
IOVA Iovance Biotherapeutics	4.2676 of 5 stars	4.4	1.0	4.2	1.7	2.5	0.6
NVAX Novavax	3.634 of 5 stars	3.2	2.0	4.7	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKT Alkami Technology	2.75	Moderate Buy	$41.00	57.24% Upside
APDN Applied DNA Sciences	3.00	Buy	$75.00	4,473.17% Upside
DY Dycom Industries	3.25	Buy	$204.38	34.30% Upside
GDYN Grid Dynamics	3.17	Buy	$19.60	28.06% Upside
IOVA Iovance Biotherapeutics	2.88	Moderate Buy	$20.25	529.86% Upside
NVAX Novavax	2.43	Hold	$18.00	209.81% Upside

Current Analyst Ratings Breakdown

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/19/2025	DY Dycom Industries	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$234.00 ➝ $200.00
3/18/2025	DY Dycom Industries	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/13/2025	ALKT Alkami Technology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$40.00
3/3/2025	ALKT Alkami Technology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$39.00 ➝ $32.00
3/3/2025	ALKT Alkami Technology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$41.00 ➝ $35.00
3/3/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $15.00
3/3/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/3/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $30.00
2/28/2025	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
2/28/2025	IOVA Iovance Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$7.50 ➝ $6.00
2/28/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKT Alkami Technology	$333.85M	7.98	N/A	N/A	$3.41 per share	7.65
APDN Applied DNA Sciences	$3.74M	0.48	N/A	N/A	$0.29 per share	5.66
DY Dycom Industries	$4.70B	0.94	$11.74 per share	12.96	$36.25 per share	4.20
GDYN Grid Dynamics	$350.57M	3.66	$0.37 per share	41.78	$5.05 per share	3.03
IOVA Iovance Biotherapeutics	$164.07M	6.42	N/A	N/A	$2.28 per share	1.41
NVAX Novavax	$682.16M	1.37	N/A	N/A	($6.04) per share	-0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKT Alkami Technology	-$62.91M	-$0.42	N/A	N/A	N/A	-14.55%	-11.31%	-9.15%	4/29/2025 (Estimated)
APDN Applied DNA Sciences	-$6.99M	-$286.00	N/A	∞	N/A	-228.12%	-101.57%	-62.43%	5/9/2025 (Estimated)
DY Dycom Industries	$218.92M	$7.92	20.02	18.86	1.29	4.91%	20.99%	8.62%	5/20/2025 (Estimated)
GDYN Grid Dynamics	-$1.76M	$0.04	388.00	∞	N/A	1.15%	-0.33%	-0.29%	5/1/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$444.04M	-$1.30	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	5/8/2025 (Estimated)
NVAX Novavax	-$545.06M	-$1.33	N/A	72.63	2.85	-32.18%	N/A	-17.05%	5/9/2025 (Estimated)

Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/27/2025	Q4 2024	ALKT Alkami Technology	$0.08	-$0.05	-$0.13	-$0.08	$89.63 million	$89.66 million
2/27/2025	Q4 2024	IOVA Iovance Biotherapeutics	-$0.26	-$0.26	N/A	-$0.26	$72.17 million	$73.69 million
2/27/2025	Q4 24	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/20/2025	Q4 2024	GDYN Grid Dynamics	$0.10	$0.04	-$0.06	$0.05	$96.00 million	$100.28 million
2/13/2025	Q1 2025	APDN Applied DNA Sciences	-$16.00	-$28.00	-$12.00	-$0.56	$1.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKT Alkami Technology	N/A	N/A	N/A	N/A	N/A
APDN Applied DNA Sciences	N/A	N/A	N/A	N/A	N/A
DY Dycom Industries	N/A	N/A	N/A	N/A	N/A
GDYN Grid Dynamics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKT Alkami Technology	0.05	3.52	3.52
APDN Applied DNA Sciences	N/A	4.72	4.53
DY Dycom Industries	0.89	3.12	2.93
GDYN Grid Dynamics	N/A	5.96	5.96
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
NVAX Novavax	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKT Alkami Technology	54.97%
APDN Applied DNA Sciences	22.22%
DY Dycom Industries	98.33%
GDYN Grid Dynamics	71.18%
IOVA Iovance Biotherapeutics	77.03%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ALKT Alkami Technology	38.00%
APDN Applied DNA Sciences	0.17%
DY Dycom Industries	4.28%
GDYN Grid Dynamics	7.20%
IOVA Iovance Biotherapeutics	12.10%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKT Alkami Technology	850	102.23 million	74.47 million	Optionable
APDN Applied DNA Sciences	70	1.10 million	55.10 million	Optionable
DY Dycom Industries	15,611	28.98 million	27.93 million	Optionable
GDYN Grid Dynamics	3,800	83.84 million	76.55 million	Optionable
IOVA Iovance Biotherapeutics	500	327.88 million	267.90 million	Optionable
NVAX Novavax	1,990	160.84 million	158.58 million	Optionable

IOVA, APDN, ALKT, GDYN, NVAX, and DY Headlines

Recent News About These Companies

Novavax (NASDAQ:NVAX) Shares Gap Down - Here's Why

April 1 at 1:17 PM | marketbeat.com

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

April 1 at 8:25 AM | zacks.com

Moderna shares drop amid FDA leadership change

March 31 at 7:32 PM | finance.yahoo.com

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out

March 31 at 7:32 PM | wsj.com

Drugmakers face market turmoil following FDA shakeup and Trump health overhaul

March 31 at 7:32 PM | usatoday.com

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says ‘wishes subservient confirmation of his misinformation and lies’

March 31 at 4:53 PM | fortune.com

Moderna, Novavax Shares Are Tumbling Monday: What's Going On?

March 31 at 10:42 AM | benzinga.com

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

March 31 at 10:13 AM | cnbc.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

March 31 at 10:05 AM | zacks.com

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

March 31 at 7:25 AM | reuters.com

Novavax, Inc. (NVAX): Among Top High-Risk, High-Reward Growth Stocks To Buy Now

March 30 at 6:15 PM | insidermonkey.com

Novavax, Inc. (NVAX): Among Top High-Risk, High-Reward Growth Stocks To Buy Now

March 30 at 6:15 PM | finance.yahoo.com

Swiss National Bank Boosts Stake in Novavax, Inc. (NASDAQ:NVAX)

March 28, 2025 | marketbeat.com

Why Novavax (NVAX) Dipped More Than Broader Market Today

March 27, 2025 | zacks.com

Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?

March 26, 2025 | benzinga.com

Moderna, Novavax, and Pfizer shares fall amid U.S. vaccine fund cuts

March 26, 2025 | za.investing.com

U.S. reportedly eyeing funding cuts to Gavi, the global vaccine alliance

March 26, 2025 | msn.com

Zacks Research Estimates Novavax FY2027 Earnings

March 25, 2025 | americanbankingnews.com

Zacks Research Comments on Novavax FY2027 Earnings

March 24, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Increases Holdings in Novavax, Inc. (NASDAQ:NVAX)

March 22, 2025 | marketbeat.com

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

March 19, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, APDN, ALKT, GDYN, NVAX, and DY Company Descriptions

Alkami Technology NASDAQ:ALKT

$26.08 -0.18 (-0.67%)

As of 09:31 AM Eastern

Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States. The company's Alkami Platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, and multi-tenant architecture. It serves community, regional, super-regional credit unions, and banks. The company was founded in 2009 and is headquartered in Plano, Texas.

Applied DNA Sciences NASDAQ:APDN

$1.64 -0.04 (-2.38%)

As of 09:30 AM Eastern

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Dycom Industries NYSE:DY

$152.18 -2.88 (-1.86%)

As of 09:31 AM Eastern

Dycom Industries, Inc. provides specialty contracting services to the telecommunications infrastructure and utility industries in the United States. The company offers engineering services to telecommunications providers, including the planning and design of aerial, underground, and buried fiber optic, copper, and coaxial cable systems; wireless networks in connection with the deployment of macro cell and new small cell sites; and program and project management and inspection personnel. It also provides construction, maintenance, and installation services for telephone companies and cable multiple system operators, such as placement and splicing of copper, fiber, and coaxial cables; tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; underground facility locating services comprising locating telephone, cable television, power, water, sewer, and gas lines; installation and maintenance of customer premise equipment, including digital video recorders, set top boxes, and modems for cable system operators; and construction and maintenance services for electric and gas utilities, and other customers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.

Grid Dynamics NASDAQ:GDYN

$15.30 -0.35 (-2.20%)

As of 09:30 AM Eastern

Grid Dynamics Holdings, Inc., together with its subsidiaries, provides technology consulting, platform and product engineering, and analytics services in North America, Europe, and internationally. It offers cloud platform and product engineering services, such as architecting, designing, and building scalable and secure cloud-based platforms and business applications; and AI/machine learning and data platform engineering services that build platforms to facilitate batch and streaming data ingestion, quality governance, orchestration, semantic modeling, observability, and analysis at scale. The company provides digital engagement services, including digital ecosystem design and implementation; and supply chain, Internet of Thing, and advanced manufacturing, which focuses on transforming traditional operations into smart and connected ecosystems. It serves customers that operate in the tech, media, telecommunications, retail, consumer packaged goods, manufacturing, and finance industries. The company was formerly known as ChaSerg Technology Acquisition Corp. and changed its name to Grid Dynamics Holdings, Inc. Grid Dynamics Holdings, Inc. was founded in 2006 and is headquartered in San Ramon, California.

Iovance Biotherapeutics NASDAQ:IOVA

$3.22 -0.04 (-1.08%)

As of 09:31 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Novavax NASDAQ:NVAX

$5.81 -0.19 (-3.17%)

As of 09:31 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time